Neo-epitope identification and quantification, immunogenic assessment, monitoring antigen presentation, soluble MHC detection

Five Services

Antigen-presenting cells (APCs) are a large group of various cells that trigger the cellular immune response by processing an antigen and exposing it in a form recognizable by T cells in the process known as antigen presentation.

The efficiency of immune therapies is highly influenced by the different steps of the antigen presentation process. Caprion offers five services related to different steps of this process.

Neo-Epitope Discovery

Efficiently identify neo-epitopes that are directly presented from the tissue of interest without the use of a predictive algorithm. Our rigorous and reproducible workflow will lead to higher quality peptides for your follow-up.

NEOEPITOPE DIRECT™

Neo-Epitope Quantification

Solidify your peptide as a target of interest by quantifying its presence. Our sensitive assays can determine the concentration of your peptides and compare them to the minimum threshold needed for T-cell response.

Interested to learn more about this service?

Contact Us

Assessing Immunogenicity

Assessing the response of the immune system to different therapies, such as drugs, vaccines, and other biologics, is an important step at various points of a drug development program. ELISpot and flow cytometry (intracellular cytokine staining) are key platforms used at Caprion to assess the immunogenicity of peptides. Leveraging its unique expertise in mass spectrometry, Caprion also performs MHC-Associated Peptide Proteomics (MAPPs) studies to identify presented peptides with potential adverse immunogenicity.

Immunogenicity Assessment

Monitoring Antigen Presentation

Assess if your drug has the capacity to affect different characteristics of antigen presentation, from MHC (major histocompatibility complex) maturation and antigenic peptide loading, to migration to the cell membrane for recognition by the T‐cell receptor.

Interested to learn more about this service?

Contact Us

Soluble MHC Detection

Soluble MHC molecules may become direct biomarkers for tumor presence, pathogen load and response to treatment. Caprion’s mass spectrometry platform can be used to detect selected biomarkers for stratifying patients in your clinical trials, ultimately ensuring an optimal treatment selection.

Interested to learn more about this service?

Contact Us

Related Services

Caprion’s expertise in ELISpot and flow cytometry allows for the comprehensive characterization of the immune response elicited by peptides identified by mass spectrometry.

Find out more:

Multiparametric Flow Cytometry ELISpot and FluoroSpot